Aspects of the present disclosure provides for contact lenses that employing Vitamin-E integrated contact lenses as a vehicle for treating conditions (e.g., bacterial keratitis and post-surgical inflammation) through at least one medicament delivery (e.g., a triumvirate medicament delivery such as a triplicate of antibiotic and anti-inflammatory drugs) to the ocular surface.